Bris­tol My­ers touts up­beat da­ta for its block­buster heart drug can­di­date

While the FDA stretch­es out its re­view for Bris­tol My­ers Squibb’s mava­camten, the phar­ma gi­ant isn’t wast­ing any time bol­ster­ing en­thu­si­asm for the heart drug.

Over the week­end Bris­tol My­ers pre­sent­ed two ma­jor sets of da­ta at the Amer­i­can Col­lege of Car­di­ol­o­gy’s an­nu­al con­fer­ence for mava­camten — which it picked up in the $13 bil­lion MyoKar­dia ac­qui­si­tion. The take-home mes­sage: Not on­ly is the car­diac myosin in­hibitor work­ing well in tri­als, but it should al­so prove to be “clin­i­cal­ly mean­ing­ful.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER